机器人与内镜协同手术治疗胃黏膜下肿瘤的临床结局与成本效果分析
这项纵向嵌套队列研究纳入314例胃黏膜下肿瘤患者,比较机器人内镜协同手术(RECS)、腹腔镜和开腹手术。倾向评分匹配后每组51例,RECS组术中出血量、首次排气时间、流质摄入时间和术后住院时间显著更低,术后3、6、12个月胃肠道症状严重程度更轻,远期生存无差异,但总住院费用更高,增量成本效果比分别为18,244和56,914元/质量调整生命年,在各支付意愿阈值下RECS具有成本效果的概率超过90%。
要点
- RECS治疗胃黏膜下肿瘤安全有效,术后恢复更快、胃肠道症状更轻。
- RECS总住院费用更高,但增量成本效果比可接受,成本效果概率超过90%。
- 三组远期总体生存和无复发生存无差异。
核心结论
- RECS是治疗胃黏膜下肿瘤安全有效的方法,术后恢复更快、胃肠道症状更少,尽管成本增加但仍具成本效果。
研究设计与样本
- 纵向嵌套队列研究,共纳入314例胃黏膜下肿瘤患者,其中RECS组61例、腹腔镜组196例、开腹组57例,采用1:1:1倾向评分匹配后每组51例。
主要发现
- 匹配后,RECS组术中出血量、首次排气时间、流质摄入时间和术后住院时间显著低于腹腔镜组和开腹组。
- RECS组术后3、6、12个月胃肠道症状严重程度显著优于腹腔镜组和开腹组。
- 三组远期总体生存和无复发生存无差异。
- RECS组总住院费用显著更高,主要因手术费用差异。
- RECS组相对腹腔镜组和开腹组的增量成本效果比分别为18,244和56,914元/质量调整生命年。
临床怎么用
- 对于胃黏膜下肿瘤,RECS可作为一种安全有效的术式选择,有利于加快术后恢复并减轻胃肠道症状。
- 尽管RECS费用较高,但成本效果分析支持其在一定支付意愿下具有经济性。
局限性
- 本研究为嵌套队列研究,非随机对照试验,可能存在残余混杂。
- 单中心研究,样本量有限,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robotic and endoscopic cooperative surgery (RECS) is an emerging and promising therapeutic approach for treating gastric submucosal tumors (GSMTs). However, the efficacy of RECS has not been well established, and its high medical costs significantly limit its application. METHODS: This nested cohort study examined patients with GSMTs managed with different surgical techniques. A total of 314 consecutive patients were enrolled in this study, including 61 patients treated with RECS, 196 patients treated laparoscopically, and 57 patients treated with open surgery. To mitigate confounding bias, 1:1:1 propensity score matching (PSM) was utilized. The perioperative outcomes, postoperative gastrointestinal symptoms, long-term outcomes, and cost-effectiveness among the three groups were compared. RESULTS: After PSM, 51 patients were included in each group. Compared with the laparoscopic and open surgical groups, the RECS group presented significantly lower intraoperative bleeding volumes, times to first flatus, times to liquid intake, and postoperative hospital stay. The severity of gastrointestinal symptoms in the RECS group was notably better than that in the laparoscopic and open groups 3, 6, and 12 months postsurgery. Regarding long-term outcomes, there were no differences in overall or relapse-free survival among the three groups. The total hospitalization cost was significantly greater in the RECS group, primarily due to surgical cost differences. The incremental cost-effectiveness ratios per quality-adjusted life year for the RECS group relative to the laparoscopic and open groups were 18,244 and 56,914 Chinese yuan (CNY), respectively. Analysis of the cost-effectiveness acceptability curves indicated that across all willingness-to-pay thresholds, the probability that RECS was cost-effective exceeded 90%. CONCLUSIONS: RECS is a safe and effective method for treating GSMTs, offering faster postoperative recovery and fewer gastrointestinal symptoms than laparoscopic and open surgeries. Despite the increased costs associated with the introduction of RECS technology, it remains a cost-effective option.
引用
- Ma L, Liu R, Hu C, et al. Clinical outcomes and cost-effectiveness analysis of robotic and endoscopic cooperative surgery for treating gastric submucosal tumors: a longitudinal nested cohort study. Surg Endosc. 2025. PMID: 40360899. doi:10.1007/s00464-025-11775-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。